FDA Expands Use of Multiple Cystic Fibrosis Medications
The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.
Obstructive Lung Disease
Vitamin D Deficiency is Associated With NTM in Cystic Fibrosis
Vitamin D deficiency is associated with a higher risk of incident nontuberculous mycobacteria respiratory isolation in adults with cystic fibrosis.
Mannitol Approved as Add-On Maintenance Therapy for Cystic Fibrosis
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Ivacaftor May Be Effective for Infants With Cystic Fibrosis and Gating Mutation
Ivacaftor was safe and associated with improvements in cystic fibrosis transmembrane conductance regulator function in infants with CF and a gating mutation.
Increased GERD Risk in End-Stage Lung Disease Without Esophageal Disease
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Intravenous vs Oral Antibiotics for P aeruginosa Treatment in Cystic Fibrosis
Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy.
Ivacaftor Approval Expanded to Include Younger Patients With Cystic Fibrosis
The approval was based on data from a phase 3 open-label safety study that included a cohort of 6 children 4 months to <6 months of age.
Cystic Fibrosis Outcomes With Concomitant Azithromycin and Tobramycin Use
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
Age may influence outcomes in lung transplant recipients with cystic fibrosis.
CFHealthHub Criteria May Be Useful to Diagnose P Aeruginosa in Cystic Fibrosis
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
-
Loading...
-
Loading...
Next post in Obstructive Lung Disease
